Maxion Therapeutics Raises $72 million (£58 million) in an Oversubscribed Series A Financing to Advance its KnotBody® Pipeline and Platform
Maxion Therapeutics Raises $72 million (£58 million) in an Oversubscribed Series A Financing to Advance its KnotBody® ...
The Pharma Letter19h
Maxion Therapeutics raises $72 million
Cambridge, UK-based biotech start-up Maxion Therapeutics, which is developing antibody-based KnotBody drugs for ion channel- ...
Business Weekly20h
International investors back Maxion Therapeutics in $72m Series A raise
Cambridge biotech Maxion Therapeutics has raised $72 million (£58m) in a Series A financing to further grow the business ...
Boehringer Ingelheim and Salipro enter drug discovery partnership
The partnership brings together Salipro’s tech for stabilising drug targets from Boehringer’s drug discovery programmes.
Salipro Biotech and Boehringer Ingelheim Enter Research and License Agreement to Accelerate Multiple Boehringer Ingelheim Pipeline Programs
Salipro Biotech AB, a Swedish biotech company specialising in the stabilisation of challenging drug targets, today announced a research and license agreement with ...
The Joplin Globe4d
Myrobalan Therapeutics Awarded a Grant from the National Multiple Sclerosis Society to Advance Development of MRO-002 in Multiple Sclerosis
Myrobalan Therapeutics, a biotechnology company developing potent, selective, and brain-penetrant oral small-molecule therapies to restore brain function, today announced a grant of over $850,000 from ...
Knowridge Science Report5d
Study shows surprising link between gut health and high blood pressure
Researchers at Monash University have uncovered how the gut—and the food we eat—affects high blood pressure. Their discovery ...
BioWorld7d
CB2 receptor as promising new target for the treatment of MASLD
Endocannabinoids are lipid mediators that interact with G protein-coupled receptors, including cannabinoid CB2 receptor (CB2R), which is mainly expressed in peripheral tissues with immune functions.
Studying structure of G protein-coupled receptor kinases could improve an array of drugs
Each cell in your body relies on precise communication with other cells to function properly. At the center of this process ...
Ophthalmology Times7d
OKYO Pharma files application for Fast Track designation with the FDA for urcosimod for the treatment of neuropathic corneal pain
Urcosmid is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor, typically found on immune ...
TMCnet7d
OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain
Fast track was first introduced by FDA to expedite development and review of drugs to treat serious conditions lacking any FDA-approved drug,” commented Gary S. Jacob, Ph.D., Chief Executive Officer ...